The Role Of Donor-Specific Anti-HLA Antibodies (DSA) In Hematopoietic Stem Cell Transplantation From Matched Unrelated Donors

S.O. Ciurea, P. Cano, M. de Lima, P.F. Thall, G. Rondon, P. Kebriaei, A. Alousi, C. Hosing, I.F. Khouri, R.E. Champlin, M. Fernandez-Vina
2010 Biology of Blood and Marrow Transplantation  
first 100 days (p \0.001), and improved 2 year survival rates (70% p 5 0.03). Our data suggest that etanercept effectively reduces TNFR1 levels at day 7 post-HCT, which has previously been correlated with transplant outcomes. The median day 7 TNFR1 levels were statistically different across conditioning regimens, and those with low TNFR1 levels had improved outcomes (FluBu4 . BCNU/Busulfan . TBI). The combination of FluBu4 with etanercept as a promising regimen for high-risk allogeneic HCT
more » ... allogeneic HCT warrants further investigation.
doi:10.1016/j.bbmt.2009.12.022 fatcat:7nhsipd5grenbfbck4v6iw7wja